Fundraising Fox
/Companies
Sign in

Triveni

58 employees on LinkedIn · 10 known investors

Find your way into Triveni

825 people in our graph share verified history with the Triveni team — schools, employers, funds. One of them is your warm intro.

Phil Ferneauunlockedknows Vishal Patel · together at Triveni (overlapped)
×5knows the team · via Defense Innovation Unit (DIU)
×5knows the team · via Merck KGaA, Darmstadt, Germany
knows the team · via Novartis Institutes for BioMedical Research (NIBR)

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.

BiotechDigital HealthHealthtech

Founders & leadership

VPVishal Patel
Vishal PatelChief Executive OfficerVishal Patel is President and CEO of Triveni Bio, a clinical-stage biotech company developing antibody therapeutics for immunological and inflammatory disorders. He previously held venture capital roles at Atlas Ventures and Flagship Pioneering, executive positions at Novartis overseeing R&D strategy, and roles at Merck KGaA; his background also includes service with the U.S. Navy, the Defense Innovation Unit, the Office of the Secretary of Defense, and senior positions in the U.S. Senate and Department of State. He holds a BS in engineering from the University of Illinois, an MBA from MIT Sloan, and a PhD in biochemistry from Harvard University.

Investors · 10

Atlas Venturelisted by Atlas VentureCambridge · $500K – $1M

How we know: Atlas Venture's portfolio page · a partner's Signal profile · press coverage · the VCSheet dataset · Not right? Tell us

Borealis Ventureslisted by Borealis VenturesHanover · $1M – $2.5M

How we know: Borealis Ventures's portfolio page · Not right? Tell us

Borealis Ventureslisted by Borealis VenturesHanover

How we know: Borealis Ventures's portfolio page · Not right? Tell us

Magnetic Ventureslisted by Magnetic VenturesBoston · $1M – $6M

How we know: Magnetic Ventures's portfolio page · Not right? Tell us

OrbiMedlisted by OrbiMedNew York · $1M – $75M

How we know: OrbiMed's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: press coverage · Not right? Tell us

InvusreportedNew York

How we know: press coverage · Not right? Tell us

Janus Henderson InvestorsreportedLondon

How we know: funding news · Not right? Tell us

Viking Global InvestorsreportedStamford

How we know: press coverage · Not right? Tell us

Funding

SEC filings, press & company announcements

$65M disclosed across 1 round · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Triveni Bio Raises $65M in Series C Fundingfinsmes.com · Jun 2026Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth - Triveni Biotriveni.bio · Jun 2026Triveni Bio Raises $115 Million Series B Financing to Expand Pipeline of Therapeutics Addressing Immunological and Inflammatory (I&I) Disordersprnewswire.com · Oct 2024

Frequently asked questions

What does Triveni do?
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases. The biotech company focuses on targeting the underlying biology of disease to change the standard of care for patients.
Who are Triveni's investors?
Triveni's investors include Ascenta Capital, Atlas Venture, Borealis Ventures, Borealis Ventures, Magnetic Ventures, OrbiMed, Fidelity Investments, Invus and 2 more.
How much funding has Triveni raised?
Triveni has disclosed $65M raised across 1 round.